TAG ARCHIVES FOR IRB

3
Nov2020

Amid both promising and worrying signs in the development of treatments and vaccines for COVID-19, and in the context of a considerable amount of scrutiny of medical research, some researchers, ethicists, and advocates are working to make sure science doesn’t lose sight of a critical issue: diversity in the clinical trial participant pool. The distribution of research benefits to participants—and the consideration of race in subject selection—is tightly woven into the Belmont Report and has been a mainstay in research ethics discussion ever since. But despite the decades-long consideration of race and ethnicity in clinical trials, many trials still don’t enroll populations that reflect the diversity of the general populace or the group affected by the condition being studied. Read more

13
Oct2020

On June 18, 2020, PRIM&R hosted a webinar, Complexity in Clinical Trial Design: A Primer on Adaptive and Platform Trials. During this webinar, Luke Gelinas and Marianne Kearney Chase defined key terms, explored ethical and regulatory challenges, and provided strategies and examples to bridge the gap between IRBs and researchers in understanding adaptive trial designs. Following the webinar, Luke and Marianne reflected on the session and attendee feedback; we're pleased to share their response with the readers of Ampersand. Read more

6
Oct2020

In reflecting on the SBER19/AER19 opening remarks by PRIM&R's Executive Director, Elisa A. Hurley, PhD on the relevance of the Belmont Report today, I feel that the Belmont Report continues to be relevant and maybe more applicable than we think dat-to-day, especially for communities intertwined with their members. Though the Belmont Report is an old document, it can always be seen with new eyes and new perspectives. Read more